Dr. Babecoff co-founded BiondVax in 2003, and has led the Company as its President and CEO since its inception. Prior to the founding of BiondVax, Dr. Babecoff had worked for 10 years in marketing and business development in the pharmaceutical industry.
In his last position as Marketing Manager at Omrix Biopharmaceuticals Ltd., Dr. Babecoff was responsible for marketing, sales training, public relations, and new product development. Some significant projects that Dr. Babecoff was then involved in include identifying West Nile Fever treatments and building cooperation with the US NIH, and forming alliances with leading international pharmaceutical companies.
Dr. Babecoff holds a D.V.M. degree from the University of Liège (ULg), Belgium and a Master of Entrepreneurship and Innovation (MEI) from the Swinburne University of Technology of Melbourne, Australia.
Tamar Ben-Yedidia, PhD – Chief Scientific Officer
Dr. Tamar Ben-Yedidia has more than 15 years of experience in the field of Immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd, BTG (Rehovot), working on the development of a recombinant Hepatitis-B vaccine.
She joined the Weizmann Institute of Science in 1994, and under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join BiondVax.
Dr. Ben-Yedidia was involved in two European Consortium projects related to evaluation of different approaches for vaccination in which leading laboratories in the field participated. Dr. Ben-Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals.
Dr. Ben-Yedidia received her Ph.D. from the Weizmann Institute after completion of her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza”.
Shimon Hassin, PhD - Chief Operating Officer
Dr. Hassin has over 10 years of experience in Biotechnology, with specific expertise in the development of biopharmaceuticals. Prior to joining the company, Dr. Hassin was co-founder and CEO of Kadimastem, an embryonic stem cell company developing an artificial pancreas for curing Juvenile Diabetes.
Before joining BiondVax, he worked at InSight Biopharmaceuticals, a leading Israeli biotechnology company active in the area of Biogenerics. In his capacity as Head of Process Development he was responsible for the manufacturing of a variety of Biogenerics such as therapeutic antibodies, cytokines and hormones.
Dr. Hassin holds a Ph.D. in Biotechnology from the University of Maryland Biotechnology Institute and was a post-doctoral associate at the University of Bergen Center of Marine Biotechnology.
Uri Ben-Or, CPA, MBA - Chief Financial Officer
Mr. Ben-Or brings over a decade of broad experience in corporate finance, accounting, M&A transactions, IPO’s and operations. He provides his services to BiondVax through CFO Direct, a company which he founded and is the Chief Executive Officer. Prior to founding CFO Direct he served as the VP Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks, where he led all the corporate finance activities, fund raising and legal aspects of the company. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PricewaterhouseCoopers.
Mr. Ben-Or holds a BA degree in Business from the College of Administration, and a MBA degree from the Bar Ilan University. He is a Certified Public Accountant.
Limor Chen, PhD – Director of Business Development
Dr. Chen has over 13 years of scientific and management experience in academia and industry. His main expertise is in research, development and commercialization of technologies in the areas of immunology, inflammation and oncology.
Before joining BiondVax, Dr. Chen worked in BioLineRx as a drug development manager leading multiple pharmaceutical and device programs towards advanced development and approval. During this period he was responsible of evaluating of in-licensing candidates, building of scientific and business strategies and identifying potential pharma partners for multi-millions $ projects.
Dr. Chen earned his PhD from the Weizmann Institute of Science in the departments of Immunology and Biophysics and was a postdoctoral fellow at MD Anderson Cancer Center in Houston, Texas and at the Sunnybrook Research Institute in Toronto.
BiondVax Pharmaceuticals Ltd. Science Park, 14 Einstein Street PO Box 4143 Ness Ziona, 74140, Israel